The pipeline TM embolization device (PED) is a braided, tubular, bimetallic endoluminal implant used for occlusion of intracranial aneurysms through flow disruption along the aneurysm neck. The authors report on two cases of giant internal carotid artery aneurysm treated with the PED. In the first case, an aneurysm measuring 26.4 mm was observed at the C3-C4 portion of the left internal carotid artery in a 64-year-old woman who underwent magnetic resonance imaging (MRI) for dizziness and diplopia. In the second case, MRI showed an aneurysm measuring 25 mm at the C4-C5 portion of the right internal carotid artery in a 39-year-old woman with right ptosis and diplopia. Each giant aneurysm was treated with deployment of a PED (3.75 mm diameter/20 mm length and 4.5 mm diameter/25 mm length, respectively). Nine months later, both cases showed complete radiological occlusion of the giant intracranial aneurysm and sac shrinkage. We suggest that use of the PED can be a therapeutic option for giant intracranial aneurysms.
INTRODUCTION
The natural history of giant intracranial aneurysms includes high morbidity and mortality from rupture. 27) Symptomatic lesions can be present in 50% of rupture cases, and the mortality rate is 60% in two years. 6) These aneurysms are often found in the cavernous and paraclinoid segments of the internal carotid artery (ICA). 2) In endovascular treatment of giant aneurysms using coils, performance of complete packing is difficult, and the rates of recurrence are high. (Fig. 2) .
Medication
Patients were pretreated with aspirin (100 mg/day) and clopidogrel (75 mg/day) for one week before PED deployment. During the procedure, intravenous
heparin was administered at 50-100 U/kg for achievement of an activated clotting time of 250-300 seconds;
this therapy was continued for 12 hours. After stenting, intravenous dexamethasone was administered at 20 mg/day for four days; subsequently, oral prednisolone was administered. Within 10 days, the oral medication was tapered as follows: 20 mg for six days, 15 mg for two days, 10 mg for one day, and 5 mg for one day. Dual antiplatelet medication was maintained for six months, and mono-medication (aspirin or clopidogrel) was prescribed indefinitely.
DISCUSSION
Interventionists encounter many difficulties in treatment of giant intracranial aneurysms. In the early endovascular treatment using only the coiling modality, retreatment was frequently required because complete occlusion of the aneurysm could not be achieved.
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Although combined use of a stent and balloon has improved the initial technique, the results are often not sustained because these aneurysms tend to require coil compaction and recanalization. Lylyk et al. 16) reported that in 53 patients with 63
aneurysms treated using PED, a 95% complete angiographic occlusion rate was achieved at 12 months of follow-up. Ninety four percent of the aneurysms arose from segmental lesions in which the vessel wall defect included more than 25% of the circumference of the parent artery, and 13% of the aneurysms were giant aneurysms. No major complications or recanalization occurred during the study period. Szikora et al. 26) reported that among 19 wide-neck aneurysms in 18 patients treated with PED, the complete occlusion rate at six months of follow up was 94.4%. Nine cases were treated with a combination of PED and coils, however, all giant aneurysms (21.1%) were treated with PED alone. No difference in occlusion rate was observed between treatment using combined coil and that using PED alone. The morbidity and mortality rates were 5.6% each. Of particular interest, they
showed that treatment with PED resulted in not only angiographic occlusion of the aneurysm but also reduction of the mass effect at the giant aneurysm.
Saatci et al. 22) reported the results of a large single-center series treated with PED; among 255 aneurysms in 191 patients, complete occlusion rates of 91.2% and 95.2% were achieved at six and 24 months, respectively, with a permanent morbidity rate of 1%
and mortality rate of 0.5%. Of these, 11.8% were giant aneurysms, and at six months of follow up, 90% of aneurysms were completely occluded.
Although use of the PED has been limited in Korea, several studies have reported unfavorable complications.
The rate of minor events was 9~16.7% and mortality was 0~6.4%. 5)9)13)15-17)22)26)28) On systematic review, stroke due to thromboembolism was 3.2% and that of in stent stenosis more than 50% was 3.5%. 19) The perforator occlusion, which is a main concern related to the PED, was reported as 2.5% by multiple applied devices, improper deployment, and resistance to antiplatelet medication. In our experience using the PED for treatment of two giant intracranial aneurysms, the device flexibility was satisfactory with good stability. In both cases, the device was successfully apposed to the parent vessel wall without difficulty using standard microcatheters.
Follow-up results confirmed that the PED affects the amount of blood flow into the sac and induces thrombosis in the sac.
